165 related articles for article (PubMed ID: 35985941)
1. Matching-Adjusted Indirect Comparisons of Lorlatinib Versus Chemotherapy for Patients With Second-Line or Later Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.
Smith S; Albuquerque de Almeida F; Inês M; Iadeluca L; Cooper M
Value Health; 2023 Jan; 26(1):64-70. PubMed ID: 35985941
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: A systematic review and network meta-analysis.
Peng Y; Zhao Q; Liao Z; Ma Y; Ma D
Cancer; 2023 Apr; 129(8):1261-1275. PubMed ID: 36748799
[TBL] [Abstract][Full Text] [Related]
3. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
[TBL] [Abstract][Full Text] [Related]
4. Lorlatinib beyond progression plus platinum/pemetrexed for ALK-positive non-small cell lung cancer patients: report of two cases.
Metro G; Baglivo S; Metelli N; Bonaiti A; Matocci R; Di Girolamo B; Mandarano M; Colafigli C; Bellezza G; Roila F; Ludovini V
J Chemother; 2023 Oct; 35(6):576-582. PubMed ID: 36537289
[TBL] [Abstract][Full Text] [Related]
5. Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.
Baldacci S; Besse B; Avrillon V; Mennecier B; Mazieres J; Dubray-Longeras P; Cortot AB; Descourt R; Doubre H; Quantin X; Duruisseaux M; Monnet I; Moro-Sibilot D; Cadranel J; Clément-Duchêne C; Cousin S; Ricordel C; Merle P; Otto J; Schneider S; Langlais A; Morin F; Westeel V; Girard N
Eur J Cancer; 2022 May; 166():51-59. PubMed ID: 35278825
[TBL] [Abstract][Full Text] [Related]
6.
Shaw AT; Solomon BJ; Besse B; Bauer TM; Lin CC; Soo RA; Riely GJ; Ou SI; Clancy JS; Li S; Abbattista A; Thurm H; Satouchi M; Camidge DR; Kao S; Chiari R; Gadgeel SM; Felip E; Martini JF
J Clin Oncol; 2019 Jun; 37(16):1370-1379. PubMed ID: 30892989
[TBL] [Abstract][Full Text] [Related]
7. The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in Sweden.
Nilsson FOL; Asanin ST; Masters ET; Iadeluca L; Almond C; Cooper M; Smith S
Pharmacoeconomics; 2021 Aug; 39(8):941-952. PubMed ID: 34080140
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of different sequential patterns after crizotinib progression in advanced anaplastic lymphoma kinase-positive non-small cell lung cancer.
Ma X; Yang S; Zhang K; Xu J; Lv P; Gao H; Qin H; Wang H; Liu X
Thorac Cancer; 2022 Jun; 13(12):1788-1794. PubMed ID: 35560808
[TBL] [Abstract][Full Text] [Related]
9. Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases.
Naito T; Shiraishi H; Fujiwara Y
Jpn J Clin Oncol; 2021 Jan; 51(1):37-44. PubMed ID: 33147606
[TBL] [Abstract][Full Text] [Related]
10. Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With
Solomon BJ; Bauer TM; Ignatius Ou SH; Liu G; Hayashi H; Bearz A; Penkov K; Wu YL; Arrieta O; Jassem J; Calella AM; Peltz G; Polli A; Thurm H; Mok T
J Clin Oncol; 2022 Nov; 40(31):3593-3602. PubMed ID: 35605188
[TBL] [Abstract][Full Text] [Related]
11. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ
Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
[TBL] [Abstract][Full Text] [Related]
12. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
13. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
Shaw AT; Kim TM; Crinò L; Gridelli C; Kiura K; Liu G; Novello S; Bearz A; Gautschi O; Mok T; Nishio M; Scagliotti G; Spigel DR; Deudon S; Zheng C; Pantano S; Urban P; Massacesi C; Viraswami-Appanna K; Felip E
Lancet Oncol; 2017 Jul; 18(7):874-886. PubMed ID: 28602779
[TBL] [Abstract][Full Text] [Related]
14. Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC.
Soo RA; Martini JF; van der Wekken AJ; Teraoka S; Ferrara R; Shaw AT; Shepard D; Calella AM; Polli A; Toffalorio F; Tomasini P; Chiu CH; Kowalski DM; Kim HR; Solomon BJ
J Thorac Oncol; 2023 Nov; 18(11):1568-1580. PubMed ID: 37295609
[TBL] [Abstract][Full Text] [Related]
15. Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer.
Yang J; Gong W
Expert Rev Clin Pharmacol; 2019 Mar; 12(3):173-178. PubMed ID: 30657349
[TBL] [Abstract][Full Text] [Related]
16. Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase-positive non-small cell lung cancer using data from ALEX and final results from ALTA-1L.
Reckamp KL; Lin HM; Cranmer H; Wu Y; Zhang P; Kay S; Walton LJ; Shen J; Popat S; Camidge DR
Curr Med Res Opin; 2022 Sep; 38(9):1587-1593. PubMed ID: 35815801
[TBL] [Abstract][Full Text] [Related]
17. Clinical Management of Adverse Events Associated with Lorlatinib.
Bauer TM; Felip E; Solomon BJ; Thurm H; Peltz G; Chioda MD; Shaw AT
Oncologist; 2019 Aug; 24(8):1103-1110. PubMed ID: 30890623
[TBL] [Abstract][Full Text] [Related]
18. Comparison of lorlatinib, alectinib and brigatinib in ALK inhibitor-naive/untreated ALK-positive advanced non-small-cell lung cancer: a systematic review and network meta-analysis.
Wang L; Sheng Z; Zhang J; Song J; Teng L; Liu L; Li Q; Wang B; Li B
J Chemother; 2022 Apr; 34(2):87-96. PubMed ID: 34139965
[TBL] [Abstract][Full Text] [Related]
19. Real-world therapeutic effectiveness of lorlatinib after alectinib in Japanese patients with ALK-positive non-small-cell lung cancer.
Goto Y; Shukuya T; Murata A; Kikkawa H; Emir B; Wiltshire R; Miura S
Cancer Sci; 2023 Jun; 114(6):2560-2568. PubMed ID: 36866958
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer.
Jo J; Kim SH; Kim YJ; Lee J; Kim M; Keam B; Kim TM; Kim DW; Heo DS; Chung JH; Jeon YK; Lee JS
Yonsei Med J; 2018 Mar; 59(2):202-210. PubMed ID: 29436187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]